Advertisement

Topics

Latest "GRAIL" News Stories

09:42 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "GRAIL" found in our extensive news archives from over 250 global news sources.

More Information about GRAIL on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about GRAIL for you to read. Along with our medical data and news we also list GRAIL Clinical Trials, which are updated daily. BioPortfolio also has a large database of GRAIL Companies for you to search.

Showing "GRAIL" News Articles 1–25 of 69

Monday 25th March 2019

NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy

Completion of Phase 1 First-in-Human Trials of Cryopreserved, Off-The-Shelf haNK Cells Leads the Way to Pivotal Phase 2 Trials in Relapsed Merkel Cell Carcinoma Funding to Support INDs for First-in-Human Targeted Off-The-Shelf NK Cells (t-haNKs) with PD-L1 and CD-19 as Tumor Targets


Sunday 10th March 2019

Medicare for all and the problem of health care on demand

The evolving politics of single-payer health care conflate the concepts of universal coverage, health care on demand and free health care. To the indiscriminate progressive mind, all three are part of the holy grail. The fly in the ointment is that highly attractive and altruistic politics runs into the brick wall of reality. As Thomas […] Find jobs at Careers by KevinMD.com. Search thousa...

Tuesday 5th March 2019

Death by patient satisfaction

The new Holy Grail of business, Customer Satisfaction — CSAT to her close friends — is a measure of how products and services supplied by a company meet customer expectations. In a marketplace where businesses compete for customers, CSAT is a key element of strategy. Why? Money. Satisfied customers buy. They come back and buy […] Find jobs at Careers by KevinMD.com. Search thousands of...


Monday 4th March 2019

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

This trial will evaluate the safety and anti-fibrotic effects of AVID200 in diffuse cutaneous systemic sclerosis patients AVID200 is a rationally designed, highly potent inhibitor of TGF-beta 1 & 3 TGF-beta 1 & 3 are the principal drivers of fibrosis in systemic sclerosis and other indications, supportin...

Thursday 21st February 2019

Know Labs Bio-RFID™ Platform Technology Identifies Blood Alcohol Levels

Know Labs, Inc. (OTCQB:KNWN) – a provider of diagnostic solutions, released today a video presentation of its Bio-RFID™ platform technology’s successful identification of blood alcohol levels. In the video presentation, CEO Phil Bosua not only discusses the Company’s use of Bio-RFID to detect blood alcohol levels, but the broad implications for its...

Wednesday 20th February 2019

Mogrify (Cell Mogrify Ltd) raises $3.7 million USD seed funding to accelerate its mission to transform cell therapy via direct cellular conversion

  Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type without going through a pluripotent stem cell- or progenitor cell-state Promises to address the unmet market need for cell types that exhibit sa...

Mogrify Raises $3.7 Million USD Seed Funding to Accelerate Its Mission to Transform Cell Therapy via Direct Cellular Conversion

Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type without going through a pluripotent stem cell- or progenitor cell-state ...

Tuesday 19th February 2019

David Oliver: Is hospital avoidance an elusive holy grail?

The first weeks of 2019 saw NHS England publish the long term plan for the NHS,1 the new five year GP contract framework,2 and the plan for universal personalised care.3 They all include an...

Monday 11th February 2019

The search for the holy grail: Promising strategies for slowing, stopping, or reversing Parkinson's disease

(IOS Press) Understanding of the processes involved in Parkinson's disease (PD) degeneration has vastly improved over the last 20 years. In this insightful review, published in the special supplement to the Journal of Parkinson's Disease, experts consider which of the existing strategies to slow down or stop the degenerative processes of PD are most likely to be successful over the next 20 years.

Friday 8th February 2019

Delivering Hope

Diffuse Intrinsic Pontine Glioma (DIPG) is every parent’s worst nightmare: a rare and incurable type of brain cancer that affects young children. Dr. Mark Souweidane decided to make curing this cancer his “Holy Grail”—and his progress since then has been impressive.

Thursday 7th February 2019

[Comment] Universal regimens or universal access to drug susceptibility testing for tuberculosis?

A universal regimen. At times this appears to be the Holy Grail in tuberculosis treatment.1 For decades, policy makers, public health specialists, and donors have argued that in order to control—and these days to “End TB”—a simplified approach that offers everyone the same regimen is our best bet.2 They argue that countries, programmes, and the people who work in them, are incapable of man...

Another attempt for the "holy grail" of oral insulin pill, inspired by tortoises! https://www.washingtonpost.com/national/health-science/pea-sized-pill-delivers-insulin-shot-from-inside-the-stomach/2019/02/07/6de3b432-2b0c-11e9-906e-9d55b6451eb4_story.h

Another attempt for the "holy grail" of oral insulin pill, inspired by tortoises! https://www.washingtonpost.com/national/health-science/pea-sized-pill-delivers-insulin-shot-from-inside-the-stomach/2019/02/07/6de3b432-2b0c-11e9-906e-9d55b6451eb4_story.html … http://science.sciencemag.org/content/363/6427/611 … pic.twitter.com/Neo2xyXFgq

Aging Is A Feature, Not A Bug

Preventing us getting old and dying has been the holy grail of biology for centuries. Money is now pouring in to ageing research, which has moved from the lunatic fringe the mainstream in the past several years. But does our current thinking stand a chance of finding that elusive "cure" for ageing?

Ageing Is A Feature Not A Bug

Preventing us getting old and dying has been the holy grail of biology for centuries. Money is now pouring in to ageing research, which has moved from the lunatic fringe the mainstream in the past several years. But does our current thinking stand a chance of finding that elusive "cure" for ageing?

Thursday 31st January 2019

Is Biogen’s Aducanumab for Alzheimer’s the Holy Grail or Cold Fusion? http://dlvr.it/QxsXvP pic.twitter.com/u4qTOHO2bQ

Is Biogen’s Aducanumab for Alzheimer’s the Holy Grail or Cold Fusion? http://dlvr.it/QxsXvP  pic.twitter.com/u4qTOHO2bQ

Tuesday 29th January 2019

Is Biogen’s Aducanumab for Alzheimer’s the Holy Grail or Cold Fusion?

Whenever a drug fails an Alzheimer’s clinical trial, analysts, investors and industry watchers immediately turn to look at Biogen. Will the company’s aducanumab be the one? Will it be the drug that will actually break the string of more than 150 drug failures?

Is There a Diagnostic Company to Rise From the Ashes of Theranos?

Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2018

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2018. Fourth quarter 2018 results: Revenue of $867 million, an 11% increase compared to $778 million in the fourth quarter of 2017 GAAP net income attributable to Illumina stockholders for the quarter ...

Wednesday 23rd January 2019

Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company’s board of directors. “We are extremely pleased to add these two experienced ...

Monday 21st January 2019

MinervaX Announces Award of 4.4 Million Euro in Investment from Novo Holdings REPAIR Impact Fund and Sunstone Capital for Further Clinical Development of the Company’s Vaccine Against Group B Streptococcus (GBS)

Copenhagen, Denmark, January 21, 2019 / B3C newswire / -- MinervaX, a privately held Danish biotech company, announces today that is has been awarded an investment of 3.6 mEUR from the Novo Holdings REPAIR Impact Fund for development of therapies to combat antimicrobial resistance (AMR). An additional investment of 0.8 mEUR was obtained from SunStone Capital. The funding will be used to help fina...

Thursday 10th January 2019

Meet a Johnson & Johnson Researcher Poised to Crack the HIV Vaccine Code

In the lead-up to the recent International AIDS Society Conference on HIV Science in the Netherlands, we sat down with Hanneke Schuitemaker, who's hard at work on the holy grail of HIV research: a preventive treatment. SOURCE: Johnson & Johnson DESCRIPTION:By Sheila Weller In 1992, as a young HIV/AIDS researcher in her native Netherlands, Hanneke Schuitemaker, Ph.D., now Vice President, ...

Wednesday 9th January 2019

Searching through diets, medications and supplements for the Holy Grail of weight loss. Hint: There is no panacea

Searching through diets, medications and supplements for the Holy Grail of weight loss

Monday 7th January 2019

High Park™ Expands Production Capacity with New Processing License from Health Canada

The licensed High Park facility located in London, Ontario allows the Company to expand its capacity to supply a range of branded adult-use cannabis products exclusively for the Canadian market High Park Holdings Ltd. (“High Park”), a wholly-owned subsidiary of Tilray, Inc. (NASDAQ:TLRY), announced today that it has received a standard process...

Sunday 6th January 2019

#Grail conducting large study for early breast cancer detection https://www.sfchronicle.com/business/article/Biotech-firm-Grail-conducting-large-study-for-13510156.php …

#Grail conducting large study for early breast cancer detection https://www.sfchronicle.com/business/article/Biotech-firm-Grail-conducting-large-study-for-13510156.php …


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks